REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.
Each of the studies being presented utilized Jasper's proprietary c-Kit Mouse™, which was developed to enable direct testing of briquilimab across a number of disease models, overcoming the limitations of standard models which do not bind antibodies directed at the human c-Kit receptor. The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA). Results from both studies demonstrated that a single dose of briquilimab protected against anaphylaxis, as measured by significantly higher core body temperatures in animals treated with briquilimab vs. untreated animals. The oral presentation covers a study that evaluated briquilimab in allergic asthma, which demonstrated that a single dose of briquilimab significantly reduced the numbers of lung mast cells and bronchoalveolar lavage-recovered eosinophils. Additionally, airway-infiltrated eosinophils and neutrophils, as well as airway hyper-responsiveness, decreased in briquilimab-treated mice, suggesting briquilimab has the potential to prevent allergic asthma via mast cell depletion.
"We are excited to present promising preclinical results from multiple studies this year at AAAAI, which indicate that briquilimab may be able to mitigate the likelihood of severe allergic reaction and anaphylaxis," said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine. "Each of these studies was conducted using the Jasper c-Kit Mouse™, which we believe enables the generation of preclinical data with superior clinical translatability, and in turn, informs our clinical development programs."
"While our initial development efforts with subcutaneous briquilimab have focused on urticaria and other dermatological conditions, we are excited by its broad potential in a variety of mast cell driven diseases," said Edwin Tucker, M.D., Chief Medical Officer. "The preclinical data being generated by our research team across numerous mast cell driven diseases is critical to determining the next indication for briquilimab clinical development this year."
Details of the presentations are as follows:
Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell Depletion
Poster Number: 024
Session Title: Therapeutic Trials in Allergic Skin Disorders and Anaphylaxis ...